 what we used to call non-alcoholic liver disease. So I think it's important to recognize that what we're seeing with the newer classes of agents in terms of pleiotropic potential benefits is not singular to the newer classes of agents. I think it's a win-win for all of us. At Johns Hopkins, I'm Elizabeth Tracy.